Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

The FDA said it will reconsider the removal of Eli Lilly’s GLP-1 drug tirzepatide from its official shortage list, after a ...

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

The macro of the moment is protein, and it’s not much of a competition. Everyone is paying attention to their protein intake ...

My own experience initially led me to believe that weight loss was just a matter of commitment and a modicum of self-control.

Consuming cinnamon may have a very small effect on weight, but it’s unlikely to deliver meaningful weight loss without other ...

In the second quarter, Hims & Hers Health reported revenue of around $316 million, up 52% from the year-ago period. It also ...

"Their effects on vaginal health are an important consideration that is often overlooked," gynecologist Melanie Bone told ...

A recent study published by the Journal of the American Medical Association (JAMA) found that patients taking the drugs ...

John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...